文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向成纤维细胞激活蛋白α的放射诊疗一体化单域抗体的临床前评价

Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.
PubMed 文献 · J Nucl Med · 2023-01-01

研究构建并筛选出靶向成纤维细胞激活蛋白α(FAP)的单域抗体4AH29,以131I和68Ga标记用于SPECT和PET显像,以131I和225Ac标记用于靶向放射核素治疗。在小鼠中,放射标记版本放射化学纯度超过95%,在FAP阳性肿瘤中快速特异性聚集,治疗组较赋形剂组延长生存,但225Ac版本后期观察到肾毒性。

要点

  • 先导单域抗体4AH29对FAP独特表位具有皮摩尔级亲和力。
  • [68Ga]Ga-DOTA-4AH29和[131I]I-GMIB-4AH29可在小鼠中实现FAP阳性肿瘤精准检测。
  • [225Ac]Ac-DOTA-4AH29和[131I]I-GMIB-4AH29治疗使荷瘤小鼠生存延长,呈剂量依赖性疗效。

核心结论

  • [68Ga]Ga-DOTA-4AH29和[131I]I-GMIB-4AH29可在小鼠中实现FAP阳性肿瘤的精准检测。
  • 治疗性[225Ac]Ac-DOTA-4AH29和[131I]I-GMIB-4AH29表现出强而持久的肿瘤靶向,在FAP阳性荷瘤小鼠中产生剂量依赖性治疗效果,但[225Ac]Ac-DOTA-4AH29后期观察到肾毒性。
  • 本研究证实放射标记单域抗体4AH29作为FAP阳性癌症放射诊疗一体化药物的潜力,值得临床评价。

研究设计与样本

  • 研究描述了一种抗FAP单域抗体的生成、筛选和表征。
  • 在小鼠中评估了以 tracer-dose 131I 和 68Ga 标记用于SPECT和PET显像、以131I和225Ac标记用于靶向放射核素治疗的显像和治疗潜力。

主要发现

  • 先导单域抗体4AH29对FAP独特表位具有皮摩尔级亲和力,可识别纯化和膜结合的FAP蛋白。
  • 放射标记版本包括[68Ga]Ga-DOTA-4AH29、[225Ac]Ac-DOTA-4AH29和[131I]I-GMIB-4AH29,放射化学纯度超过95%,有效结合重组人FAP蛋白和FAP阳性GM05389人成纤维细胞。
  • 放射标记化合物在FAP阳性U87-MG胶质母细胞瘤中快速特异性聚集,在淋巴结、子宫、骨和皮肤中低但特异性摄取(约2-3 %IA/g)。
  • 未结合[131I]I-GMIB-4AH29肾脏清除快(24小时后<1 %IA/g),而[225Ac]Ac-DOTA-4AH29清除较慢(24小时后8.07 ± 1.39 %IA/g,96小时后2.47 ± 0.18 %IA/g)。
  • 接受[225Ac]Ac-DOTA-4AH29和[131I]I-GMIB-4AH29治疗的小鼠较接受赋形剂溶液者生存延长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein α (FAP) is highly expressed on cancer-associated fibroblasts of epithelial-derived cancers. Breast, colon, and pancreatic tumors often show strong desmoplastic reactions, which result in a dominant presence of stromal cells. FAP has gained interest as a target for molecular imaging and targeted therapies. Single-domain antibodies (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and targeted therapy. Methods: We describe the generation, selection, and characterization of a sdAb against FAP. In mice, we assessed its imaging and therapeutic potential after radiolabeling with tracer-dose 131I and 68Ga for SPECT and PET imaging, respectively, and with 131I and 225Ac for targeted radionuclide therapy. Results: The lead sdAb, 4AH29, exhibiting picomolar affinity for a distinct FAP epitope, recognized both purified and membrane-bound FAP protein. Radiolabeled versions, including [68Ga]Ga-DOTA-4AH29, [225Ac]Ac-DOTA-4AH29, and [131I]I-guanidinomethyl iodobenzoate (GMIB)-4AH29, displayed radiochemical purities exceeding 95% and effectively bound to recombinant human FAP protein and FAP-positive GM05389 human fibroblasts. These radiolabeled compounds exhibited rapid and specific accumulation in human FAP-positive U87-MG glioblastoma tumors, with low but specific uptake in lymph nodes, uterus, bone, and skin (∼2-3 percentage injected activity per gram of tissue [%IA/g]). Kidney clearance of unbound [131I]I-GMIB-4AH29 was fast (<1 %IA/g after 24 h), whereas [225Ac]Ac-DOTA-4AH29 exhibited slower clearance (8.07 ± 1.39 %IA/g after 24 h and 2.47 ± 0.18 %IA/g after 96 h). Mice treated with [225Ac]Ac-DOTA-4AH29 and [131I]I-GMIB-4AH29 demonstrated prolonged survival compared with those receiving vehicle solution. Conclusion: [68Ga]Ga-DOTA-4AH29 and [131I]I-GMIB-4AH29 enable precise FAP-positive tumor detection in mice. Therapeutic [225Ac]Ac-DOTA-4AH29 and [131I]I-GMIB-4AH29 exhibit strong and sustained tumor targeting, resulting in dose-dependent therapeutic effects in FAP-positive tumor-bearing mice, albeit with kidney toxicity observed later for [225Ac]Ac-DOTA-4AH29. This study confirms the potential of radiolabeled sdAb 4AH29 as a radiotheranostic agent for FAP-positive cancers, warranting clinical evaluation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dekempeneer Y, Massa S, Santens F, et al. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α. J Nucl Med. 2023. PMID: 38040444. doi:10.2967/jnumed.123.266381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。